Adaptive Biotechnologies Corp (ADPT) Q1 2026 Earnings Call Transcript

Why It Matters

The results prove Adaptive’s MRD platform can scale profitably while expanding into high‑margin immune‑receptor data services, positioning the firm as a key player in precision oncology diagnostics and biotech data licensing.

Key Takeaways

• Revenue $277M, 55% YoY growth.
• MRD revenue $212M, 46% increase, profitable.
• clonoSEQ tests 30k, 43% YoY rise.
• ASP $1,307, up 17%; 2026 target $1,400.
• Immune Medicine deals with Pfizer, cash burn $15‑20M.

Pulse Analysis

Adaptive Biotechnologies’ 2025 earnings underscore the accelerating demand for minimal residual disease (MRD) diagnostics in hematologic oncology. The clonoSEQ assay, now performing over 30,000 tests in the fourth quarter, benefits from broader guideline inclusion, expanded EMR integrations, and a shift toward blood‑based sampling that now accounts for nearly half of all orders. This operational momentum, combined with the rollout of NovaSeq X+ sequencers, has lifted sequencing gross margins to 71% in Q4, reinforcing the company’s ability to deliver high‑value, high‑throughput molecular testing at scale.

Financially, Adaptive turned the corner from loss to profitability in its core MRD segment, posting adjusted EBITDA of $12.2 million for the year and a 66% full‑year gross margin. Revenue growth was powered by a 17% rise in average selling price, reflecting successful renegotiations with major payer contracts and improved revenue‑cycle management that boosted commercial collections by 74%. The firm’s cash position of $227 million provides ample runway to meet its 2026 guidance, which targets MRD revenue of $255‑$265 million, an ASP of $1,400, and positive free cash flow, while maintaining disciplined operating expenses.

Beyond diagnostics, Adaptive’s Immune Medicine platform is gaining traction through strategic data‑licensing deals, notably two agreements with Pfizer that monetize its extensive T‑cell receptor (TCR) and antigen datasets. By focusing capital on AI/ML modeling and expanding its proprietary immune‑receptor library, the company aims to lower cash burn to $15‑$20 million in 2026 while unlocking new revenue streams in drug discovery and autoimmune research. Execution risk remains around payer contract renewals and seasonal cash utilization, but the combined growth in MRD testing and immune‑data services positions Adaptive as a versatile, high‑growth biotech asset.